YAP1 and cancer: Ursolic acid combined with Doxorubicin inhibits the YAP/TAZ signaling pathway by promoting YAP degradation while simultaneously blocking the Akt/GSK3β signaling pathway, demonstrating the potential of multi-target interventions in cancer treatment (138).